Related Experiment Video
Updated: Jun 3, 2026
10:38
In Vivo Alkaline Comet Assay and Enzyme-modified Alkaline Comet Assay for Measuring DNA Strand Breaks and Oxidative DNA Damage in Rat Liver
Published on: May 4, 2016
16.1K
Considerations for Clinical Trial Design in Relapsed and Refractory Osteosarcoma: An FDA Symposium
Kristin M Wessel1, Katherine A Janeway2,3, Lara E Davis4,5
1Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland.
Summary
Osteosarcoma, a rare bone cancer, urgently needs new treatments for relapsed and refractory cases. Collaborative efforts are essential to design clinical trials that effectively evaluate new therapies for this challenging pediatric cancer.
Area of Science:
- Pediatric Oncology
- Bone Tumors
- Cancer Research
Background:
- Osteosarcoma is the most common primary malignant bone tumor in children and adolescents.
- Metastatic disease affects 10-20% of patients, with significantly lower survival rates.
- No standard FDA-approved therapies exist for relapsed or refractory osteosarcoma.
Purpose of the Study:
- To summarize key challenges and future directions in clinical trial design for relapsed and refractory osteosarcoma.
- To highlight the need for innovative trial designs to accelerate drug development.
- To foster collaboration among stakeholders for improved patient outcomes.
Main Methods:
- Summary of discussions from an FDA Oncology Center of Excellence educational symposium.
- Involved patient advocates, regulators, and academic thought leaders.
- Focused on challenges in clinical trial design and implementation for osteosarcoma.
Main Results:
- Progress is hindered by complex biology, rarity, and unreliable outcome measures like objective response rate (ORR).
- Current trial designs may not adequately capture drug efficacy in this population.
- Collaboration is crucial to develop patient-acceptable trials providing sufficient evidence for approval.
Conclusions:
- Advancing treatment for relapsed/refractory osteosarcoma requires innovative clinical trial designs.
- Intentional collaboration among patients, regulators, and researchers is vital.
- Future efforts must focus on trials that yield robust evidence of safety and efficacy.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...